Industry

Capital will advance BigHat’s internal pipeline of therapeutics to patients, expand platform capacity 10-fold, and accelerate strategic partnerships SAN MATEO, Calif.–(BUSINESS WIRE)–BigHat Biosciences, a biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, today announced it has raised a $75 million Series B funding round, led by Section … [Read more…]

Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America. The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform. The study is supported in part by the Alberta … [Read more…]

ELYRIA, Ohio–(BUSINESS WIRE)–Invacare Corporation (NYSE: IVC) (“Invacare” or the “company”) announces that it will release its financial results for the second quarter ended June 30, 2022, after the market closes on Monday, August 8, 2022. The company will provide a live conference call and webcast to discuss these financial results on Tuesday, August 9, 2022, … [Read more…]

Jeremy Kean joins the leading customer-centric dental AI company to drive hyper-growth BOSTON–(BUSINESS WIRE)–VideaHealth, the leading dental diagnostic AI solution, today announced the addition of healthcare veteran Jeremy Kean as vice president of customer success. Kean brings more than 20 years of customer success experience to the company’s executive team, including successful tenures at WebMD … [Read more…]

Series B financing will accelerate clinical trials and global commercialization of the company’s Symani® Surgical System PISA, Italy–(BUSINESS WIRE)–Medical Microinstruments, Inc. (MMI), a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced it has raised $75 million in Series B financing. Deerfield Management led the round with participation from new investors, … [Read more…]

-Top line data expected in second half of 2023- ROCKVILLE, Md.–(BUSINESS WIRE)–#MCC–Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced dosing of the first patient in the company’s Phase 1 study evaluating ITI-3000, a plasmid DNA (pDNA) vaccine targeting patients with … [Read more…]

LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended July 1, 2022 on Wednesday, August 10, 2022 after the market close. STAAR will host a conference call … [Read more…]

FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #AAD–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced an upcoming presentation on DecisionDx®-Melanoma, the Company’s risk stratification gene expression profile (GEP) test, at the 2022 American Academy of Dermatology (AAD) Innovation Academy, being held in Vancouver, Canada, July 21-24. DecisionDx-Melanoma is designed … [Read more…]

BENSALEM, Pa.–(BUSINESS WIRE)–Healthcare Services Group, Inc. (NASDAQ:HCSG) (the “Company”) reported for the three months ended June 30, 2022 revenue of $424.9 million and net income of $6.8 million, or $0.09 per basic and diluted common share. The Company’s Board of Directors declared a quarterly cash dividend of $0.21375 per common share, the 76th consecutive increase … [Read more…]

HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the dosing of the first patient in their multicenter Phase 2 trial assessing efficacy and safety of CDR132L in 280 patients with reduced left ventricular ejection fraction after myocardial infarction (HF-REVERT). CDR132L is an oligonucleotide-based … [Read more…]